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Abstract Dramatic progress has been made recently in
identifying both viral and cellular molecules responsible for
binding and fusion of HIV-1 to target cells. In vivo, HIV-1
infection is transmitted by viruses that recognize chemokine
receptor CCR5, while viruses isolated at later stages of HIV
disease often recognize another chemokine receptor, CXCR4. It
is still not understood how this molecular tropism of HIV-1 is
translated into the virus’ ability to compromise normal cell
functions, which results in impairment of lymphoid tissue and
causes AIDS. Here, we discuss how the new molecular findings
might relate to HIV pathogenesis in cells and tissues.
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1. Introduction
AIDS is the ¢rst pandemic to start in the era of molecular
biology. As a result, we know much about the molecules
encoded by the viral genome. In contrast, however, we
know relatively little about the mechanisms of viral patho-
genesis. AIDS is a complex disease, in part because HIV in-
fects the cells that ¢ght infection and disrupts multiple, little
understood cell interactions in the lymphoid system. More-
over, the virus evolves rapidly and continuously over many
years in the body under yet unidenti¢ed selective pressures,
and its properties can be strikingly di¡erent early in infection
compared with later, when severe immunode¢ciency occurs
[1,2].
Until recently, HIV-1 isolates were classi¢ed according to
their ability to infect and induce syncytia in various cells lines
or blood-derived cells in culture. Initial HIV-1 infection is
transmitted by viruses that, in vitro, are able to infect both
T lymphocytes and monocyte-derived macrophages, but that
fail to induce syncytia in several test cell lines. In contrast,
viruses isolated at later stages of HIV disease often have ac-
quired the ability to induce syncytia in the same test cell lines
but lose the ability to infect primary macrophages. The former
are de¢ned as M-tropic, or syncytia-inducing (SI), the latter
are classi¢ed as T-tropic, or non-SI. Recently, it was discov-
ered that various isolates recognize particular chemokine re-
ceptors on the target cells. As a result, a vague and contro-
versial classi¢cation of HIV-1 based on a complex interaction
of virus with particular cells has now been replaced by one
built on the ¢rmer basis of the viral molecular characteristics
[3]. This new classi¢cation may have a profound impact on
HIV research, similar to the impact of Mendeleev’s Periodic
Table on chemistry. The next task is to correlate the molec-
ular characteristics of HIV and its counterparts on target cells
with the mechanisms by which HIV compromises normal cell
functions, using this knowledge to understand how HIV im-
pairs the more complex lymphoid tissue and causes AIDS.
The aim of this minireview is to discuss how the new
molecular ¢ndings relate to HIV pathogenesis in cells and
tissues.
2. Molecular tropism: HIV co-receptors
HIV infection starts with the binding of the viral envelope
to the target cell surface via the viral envelope glycoprotein
(Env) gp120, eventually enabling the virus to fuse with the
plasma membrane. The ¢rst cellular component of this inter-
action was identi¢ed several years ago as CD4, a member of
the immunoglobulin superfamily. CD4 is necessary but not
su⁄cient for fusion. The strongest indication that a co-factor
is required is the inability of non-primate cells transfected
with human CD4 to fuse with HIV-1- or with Env-expressing
cells (reviewed in [4]).
It took, however, almost a decade more to identify a fusion
co-factor [5]. The discovery of this molecule, originally named
fusin, by Edward Berger and his colleagues [5] was a triumph
of the purely molecular biological approach. They repeatedly
subdivided a human cDNA library, made from a cell type
permissive for HIV infection, transfected CD4-expressing
non-human cells with this cDNA, and then tested the resul-
tant cellular clones for their ability to fuse with Env-express-
ing cells. Three other HIV-1 co-receptors were reported only
weeks after fusin by ¢ve independent groups [6^10], and a few
others have been reported since [11,12].
All known HIV co-receptors belong to the chemokine re-
ceptor branch of the superfamily of seven-transmembrane G-
protein coupled receptors [13]. Chemokine receptors bind a
subfamily of cytokines that attract leukocytes to sites of in-
£ammation [4,13]. According to a new nomenclature, fusin
was renamed CXCR4. In vitro, HIV-1 utilizes various chemo-
kine receptors, but evidence for in vivo usage has been pub-
lished only for CCR5 and CXCR4 (see [4,14] and references
therein).
Chemokine receptors on the cell surface are recognized by
viral gp120, which forms a three-molecule complex with CD4
[15], but many details of this process remain unclear. Re-
cently, a CD4-independent HIV-1 isolate, which (similar to
HIV-2 [16]) uses only chemokine receptors for viral entry,
was described [17]. Thus, the categorization of HIV-1-binding
cell surface molecules into receptors and co-receptors re£ects
FEBS 20620 14-8-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 8 5 8 - 8
*Fax: (1) (301) 4800857 or (1) (301) 5940813.
E-mail: margolis@helix.nih.gov
FEBS 20620 FEBS Letters 433 (1998) 5^8
merely the history of their discovery rather than their relative
importance.
The discovery of the molecular tropism of HIV-1 now al-
lows molecular classi¢cation of these viruses according to
their co-receptor usage (molecular tropism) as X4 (CXCR4-
tropic), R5 (CCR5-tropic), or X4R5 (dual tropic) [3].
Shortly before HIV co-receptors were discovered, Gallo and
his colleagues puri¢ed three anti-HIV substances, RANTES,
MIP-1K and MIP-1L [18], which turned out to be CCR5-bind-
ing chemokines. Later a CXCR4-speci¢c chemokine SDF-1
was identi¢ed [19]. Together with cell lines expressing CD4
and a single co-receptor, chemokines provide new research
tools to determine which co-receptor is used by various iso-
lates to infect di¡erent types of cell.
3. Cell infection: relation of molecular to cellular tropism of
HIV
T lymphocytes, dendritic cells, monocytes/macrophages and
brain glial cells are the main cells that co-express chemokine
receptors and CD4+ [11], making them the natural targets for
HIV-1 infection. In the laboratory, all HIV-1 isolates are uni-
versally propagated in peripheral blood mononuclear cells
(PBMC) [20]. Cultured monocyte-derived macrophages, and
various T cell lines are more selective, some isolates infecting
only one type.
Designation of HIV-1 isolates as M-tropic or T tropic dis-
guises the fact that in vitro both infect dendritic cells and
activated T cells [3,4]. At molecular level the situation is less
confusing, and also molecular tropism correlates with M- or
T-tropism (see [4,14]) : R5 HIV isolates are M-tropic while X4
isolates are T-tropic; dual-tropic R5X4 viruses have also been
identi¢ed.
However, molecular tropism does not fully explain the
cause of cellular tropism. For example, it is not clear why
X4 HIV poorly infects macrophages even though these cells
express both CD4 and CXCR4 (as well as CCR5) (see [12]).
Whatever the explanation, the selective resistance of in vitro
macrophages to X4 HIV-1 may be related to the fact that R5,
rather than X4, HIV-1 transmits infection in vivo. Normally,
mucosal macrophages and dendritic cells are the ¢rst cells to
meet an antigen and to carry it to the regional lymph nodes to
trigger an immune response [21]. This natural mechanism of
defense is also used by HIV-1 for its transport to the lymph
nodes [22]. If also in vivo macrophages are infectible only by
R5 HIV-1 it would partially explain why only R5 viruses
transmit infection. However, it is not clear how well cellular
tropism in in vitro experiments re£ects the spectrum of target
cells in vivo. Moreover, it was found that the expression pat-
terns of CCR5 and CXCR4 on the surface of macrophages
[23] or dendritic cells [24] in culture di¡er from those present
in vivo. Obviously, in vitro cells do not display some impor-
tant physiological parameters that are critical for HIV infec-
tion in vivo.
Cell activation that modulates co-receptor expression
[25,26] and thus HIV infection, may be one of these pa-
rameters. Moreover, the virus itself may send an activation
signal through the chemokine receptors [27,28] ¢ne-tuning of
cells for viral replication. Such a signal is not required for in
vitro PBMC infection [29^31] since such cells are already ar-
ti¢cially activated by PHA and IL-2 to be able to propagate
virus [20].
Cell activation may explain why, in vitro, CC-chemokines
paradoxically enhance R5 HIV replication in macrophages
instead of inhibiting it [32]. In vitro, in contrast to PBMC,
macrophages do not need to be over-stimulated for HIV-1
infection, and stimulation by CC chemokines may enhance
replication of those viral particles that enter cells through
unoccupied CCR5 receptors. Such a phenomenon was not
observed in over-stimulated PBMC or in constitutively stimu-
lated T cell lines, in which CC chemokines inhibit R5 HIV-1
infection [6^8,18]. Recently, however, CC chemokine-en-
hanced HIV-1 replication was also described for T cells in
lymphoid tissues ex vivo [33], in which lymphocytes do not
require exogenous stimulation for productive HIV infection
[34,35].
This is further evidence that one may not be able to extrap-
olate results of experiments relating to HIV co-receptor usage
directly to cells in vivo. In conclusion, HIV-1 cellular tropism
appears to be a function of the co-receptor tropism of HIV,
albeit not a simple one.
4. Lymphoid tissue: HIV co-receptors and viral pathogenesis
Nowadays, it is generally accepted [2] that the critical events
of HIV disease take place within lymphoid tissue, in which
complex interactions between both infected and uninfected
cells occur. 98% of CD4+ T lymphocytes, the potential
HIV-1 targets, reside in lymphoid tissue. Even during the
apparent clinical ‘latency’ stage of HIV disease, HIV contin-
ues to replicate in lymphoid tissue [36], which eventually de-
teriorates and fails to replenish the massive loss of lympho-
cytes [37].
Suspensions of peripheral blood lymphocytes in vitro or
transfected cell lines, which have been used to obtain the
vast majority of experimental data on HIV infection, lack
the complex intercellular interactions and the rich cellular
repertoire typical of lymphoid tissue. Thus, for experimental
studies of AIDS, HIV pathogenesis may be more closely ap-
proximated using integral lymphoid tissue.
Two experimental systems have been developed to study
HIV pathogenesis in whole lymphoid tissue: HIV-1-infected
SCID-hu mice with transplanted human neonatal thymus [38],
explants of human adult lymph nodes or tonsils [34,35] or of
neonatal human thymus [39,40]. All these systems support
replication of HIV-1. In ex vivo lymphoid tissues, X4 HIV-1
infection is associated with severe depletion of CD4+ T lym-
phocytes, while R5 viruses deplete CD4+ T lymphocytes only
mildly [34,35,41]. This correlates with di¡erent stages of HIV
disease in vivo: the early stages are dominated by R5 viruses,
while the late stages, associated with CD4+ T lymphocyte
depletion and immunode¢ciency, are often dominated by X4
or dual tropic HIV-1 [42,43].
Why do X4 isolates deplete CD4+ T cells in human
lymphoid tissue ex vivo, while R5 do not? Perhaps the life
and death of an individual T cell depend on which co-receptor
the virus has used to infect the T cell. Alternatively, R5
and X4 HIV may infect di¡erent CD4+ T cell subsets, only
those infected by X4 dying. These questions remain to be
answered.
The ex vivo studies [35,44,45] mimic clinical observations
[36,46] on the apparent discrepancy between the small number
of productively infected cells and massive cell killing by X4
viruses. Apparently, besides the infected cells, uninfected (by-
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stander) cells may be killed as well [47,48]. Many mechanisms
have been proposed to explain this, including an excess of
cytotoxic viral proteins (reviewed in [49]), oxidative stress
[50,51], secreted cellular factors, or defective cell-cell interac-
tions [2,47,49], although none of these hypotheses has yet
been proved. At least for ex vivo tissue, productively infected
cells may die quickly [37] ; even though a relatively small
number of them die at any time, the integrated number dying
over weeks of infection may account for all cell death without
invoking the bystander death hypothesis. Ultimately, this con-
troversy should be resolved by the development of methods to
monitor individual HIV-infected cells in ex vivo experiments
with whole tissues.
Many other aspects of HIV pathogenesis also require tissue
integrity. One of them is immunode¢ciency, the hallmark of
HIV disease, which can now be studied in human lymphoid
tissue ex vivo [52]. Ex vivo antigen challenge of these tissues
leads to production of speci¢c antibodies. This response is
dramatically inhibited by X4, but not by R5 HIV-1 isolates
[52]. This provides experimental evidence that a switch in HIV
co-receptor tropism may be a cause of immunode¢ciency in
vivo rather than merely an associated phenomenon.
What is the driving force for such a switch? Endogenous
CC chemokines may play an important role [2] in this process.
Their upregulation in X4-infected but not in R5-infected hu-
man lymphoid tissues, which has been observed ex vivo [33],
may inhibit R5 viruses, giving advantage to X4 infection.
Whatever the factors regulating tissue infection, they are ei-
ther secreted locally or transmitted in the course of cell-cell
contacts. In both cases, the relative positioning of the cells
producing and accepting these factors should be extremely
important.
The critical role of tissue cytoarchitecture in HIV patho-
genesis was fully appreciated only relatively recently [36],
and experimental approaches to address this problem have
still to be developed. As a result, this ¢eld poses many more
questions than it has answers.
5. Conclusions
Signi¢cant progress has been made in identifying both viral
and cellular molecules responsible for virus binding and
fusion to target cells. Primary cellular targets for HIV-1 that
harbor virus and transfer it into lymphoid organs have
been identi¢ed, and their relevant molecular characteristics
have been extensively studied. The next challenge is to un-
derstand how these newly discovered molecular and cellu-
lar mechanisms of HIV infection ¢t into the integral picture
of HIV pathogenesis in vivo. More generally, a multidisci-
plinary approach to HIV pathogenesis o¡ers a better oppor-
tunity to determine how a natural multi-cellular system
operates and how a relatively simple pathogen, whose molec-
ular characteristics are known, diverts this operation to its
own bene¢t.
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